Logo
x

Search

Subscribe Now

Exercises

Gilead Exercises its Options with Arcus for its Three Clinical-Stage Programs to Treat Cancers

Gilead Exercises its Options with Arcus for its Three Clinical-Stage Programs to Treat Cancers

  • November 19, 2021
Takeda to Acquire Maverick for ~$525M

Takeda to Acquire Maverick for ~$525M

  • March 10, 2021
BMS Exercises its Option to Globally License Obsidian's CD40L Cell Therapy

BMS Exercises its Option to Globally License Obsidian's CD40L Cell Therapy

  • September 16, 2020
AbbVie Exercises its Option to License Morphosys' αvβ6 Integrin Inhibitor Program for Fibrotic Disease

AbbVie Exercises its Option to License Morphosys' αvβ6 Integrin Inhibitor Program for Fibrotic Disease

  • August 25, 2020
Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478

Neurocrine Biosciences Exercises its Option with Idorsia for ACT-709478

  • May 12, 2020
Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

  • February 26, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.